Cross-source identity
National Provider Identifier 1457613986 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1457613986 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1457613986 | 113 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1457613986 | 18 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 8f78dca3… | Canonical resolved node · 4 identifier(s) · 0 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,547 | 14 |
| Travel and Lodging | $11,402 | 42 |
| Consulting Fee | $10,249 | 5 |
| Food and Beverage | $2,957 | 51 |
| Manufacturer | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $75,637 | 91 |
| Regeneron Pharmaceuticals, Inc. | $9,746 | 12 |
| Deciphera Pharmaceuticals Inc. | $125 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Erivedge(Vismodegib) | 24 | $264,885 |
| Dupixent Syringe(Dupilumab) | 15 | $86,215 |
| Otezla(Apremilast) | 15 | $71,250 |
| Acitretin | 28 | $9,398 |
| Tacrolimus | 22 | $3,486 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| 1 |
| Genzyme Corporation | $122 | 3 |
| Novocure Inc. | $91 | 1 |